DYNAKIN DRUG MODELING CONSULTING TEAM Revenue and Competitors

Dynakin is a Strategic Consulting Company specialized in Model Informed Drug Development (MIDD). Dynakin drives the shortest road to your drug development success, leveraging state-of-the-art Industry and regulatory standard pharmacometric methods to maximize efficiency and minimize risk and costs in development. The company has extensive knowledge in performing and in accompanying partners and clients applying PK/PD Modeling and Simulation tools through the R&D for drug development from pre-clinical, FTIM, and Phase I up to Phase III and IV clinical trials. Dynakin’s DMC group has a strong presence in applying Modeling & Simulation in regulatory aspects of drug development and bioequivalence. Dynakin’s senior level regulatory experts successfully accompanied products to the EMA and other European Member State agencies as BfarM, MHRA, and also to FDA and ANVISA. Another field of applied expertise of these Modeling and Simulation tools are special populations and trial design and execution in these, including presentation of the first pediatric investigation plan (PIP) to the EMA. Several PIPs plans have followed to different regulatory agencies. Whether you are working on a new chemical entity, a drug repurposing, or a complex generic, we invite you to contact us to find out how we can bring your project to success.